Amgen
AMGNApprovedAmgen is a leading global biotechnology company and pioneer in using living cells to make biologic medicines, with a market valuation of $187.5 billion. The company focuses on serious illnesses across cardiovascular, metabolic, bone health, inflammation, and oncology therapeutic areas, with multiple programs in Phase 3 clinical development.
AMGN · Stock Price
Historical price data
AI Company Overview
Amgen is a leading global biotechnology company and pioneer in using living cells to make biologic medicines, with a market valuation of $187.5 billion. The company focuses on serious illnesses across cardiovascular, metabolic, bone health, inflammation, and oncology therapeutic areas, with multiple programs in Phase 3 clinical development.
Technology Platform
Biologic medicines using living cells to create therapeutic proteins and antibodies
Pipeline Snapshot
10001000 drugs in pipeline, 334 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| Etelcalcetide | Secondary Hyperparathyroidism | Phase 3 |
| Evolocumab + Ezetimibe + Placebo to Evolocumab | Hyperlipidemia | Phase 3 |
| Isatuximab | Multiple Myeloma | Phase 3 |
| 50 mg Etanercept + Enbrel liquid | Rheumatoid Arthritis | Phase 3 |
| Carfilzomib + Carfilzomib + Lenalidomide + Dexamethasone | Relapsed or Refractory Multiple Myeloma | Phase 3 |
Funding History
1Total raised: $5B
FDA Approved Drugs
25Opportunities
Risk Factors
Competitive Landscape
Amgen competes with major biotechnology companies including Genentech/Roche, Gilead Sciences, and Biogen, while also facing biosimilar competition. The company maintains competitive advantages through established manufacturing capabilities, strong IP portfolio, and diversified pipeline across multiple therapeutic areas.
Company Info
Trading
Contact
Therapeutic Areas
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile